AI assistant
MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2012
Dec 16, 2012
65396_rns_2012-12-16_b7420508-1c2b-4be0-9839-a4845345822f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [115 x 58] intentionally omitted <==
17 December 2012
MAYNE PHARMA SUCCESSFULLY COMPLETES PLACEMENT
Mayne Pharma Group Limited (Mayne Pharma; ASX: MYX) is pleased to announce that it has successfully completed the book build for the placement announced on 14 December 2012 for approximately 61 million shares at A$0.295 per share to raise gross proceeds of A$18.0 million.
Mayne Pharma’s CEO, Scott Richards, said “The placement was heavily oversubscribed with strong support received from existing and new shareholders, which is an endorsement of the Mayne Pharma business as well as the acquisition.”
Settlement of the placement is expected to be completed on 20 December 2012 and these new shares are expected to be issued and commence trading on the ASX on a normal settlement basis on 21 December 2012.
As indicated in the announcement on 14 December 2012, Mayne Pharma also plans to offer eligible shareholders in Australia and New Zealand the opportunity to participate in a Share Purchase Plan, up to the maximum value of A$10,000 per eligible shareholder at the placement price. Full details of the share purchase plan will be set out in the documents to be sent to shareholders in early January 2013.
Mayne Pharma expects its trading halt to be lifted and ordinary shares to commence trading from market open today.
-ENDS-
For further information contact:
Scott Richards (CEO) 08 8209 2410 Lisa Pendlebury (Investor Relations) 0419 548 434, [email protected]
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS
This document may not be released or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any securities described in this document have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.